News

Under the strategic collaboration, the companies will develop and commercialise compounds in Takeda’s early-to-mid-stage psychiatry pipeline. As part of the deal, Neurocrine has secured an exclusive licence for

The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is composed of a composite of CV death, nonfatal myocardial infarction or nonfatal

The data demonstrated daratumumab SC in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a significantly higher haematologic complete response rate (CR), 53 percent vs. 18 percent

The approval of Zepzelca is for treating metastatic small cell lung cancer in adults whose disease has progressed on or after platinum-based chemotherapy. The alkylating drug, which is

PML is a rare, aggressive, opportunistic brain infection caused by the reactivation of John Cunningham virus (JCV) in immunocompromised individuals. “The greatest barrier between PML patients and recovery

The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.

With today’s agreement, the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the

The approval allows the dispersible tablet formulation of dolutegravir, in combination with other antiretroviral treatments, to be used in treatment-naïve paediatric patients aged more than four weeks and

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. “Orphan Drug Designation for DKN-01